608515-48-6

Basic information

• Product Name: Acetamide, N-[(2-bromophenyl)methyl]-2,2-diethoxy-
• CAS NO: 608515-48-6
• Molecular Formula: C13H18BrNO3
• Molecular Weight: 316.195
• Mol File: 608515-48-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Acetamide, N-[(2-bromophenyl)methyl]-2,2-diethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[(2-bromophenyl)methyl]-2,2-diethoxy-(608515-48-6)
• EPA Substance Registry System: Acetamide, N-[(2-bromophenyl)methyl]-2,2-diethoxy-(608515-48-6)

Safety Data

• Hazardous Substances Data: 608515-48-6(Hazardous Substances Data)

Upstream product

• 3959-05-5 2-bromobenzylamine 
• 68057-09-0 diethoxyacetyl chloride 

Downstream Products

• 928115-20-2 8-(1,1'-biphenyl-4-yl)isoquinolin-3-yl triisopropylsilyl ether 
• 928115-22-4 8-(1,1'-biphenyl-4-yl)isoquinolin-3-yl trifluoromethanesulfonate 
• 928115-19-9 8-(1,1'-biphenyl-4-yl)isoquinolin-3-yl trifluoromethanesulfonate 
• 928115-21-3 8-(1,1'-biphenyl-4-yl)isoquinolin-3-ol 
• 1026411-31-3 8-(2,5-dihexyl-4'-methoxy-biphenyl-4-yl)-isoquinolin-3-ol 
• 608515-49-7 8-bromoisoquinolin-3-ol 
• 880644-68-8 4,4'-(3,3'-biisoquinoline-8,8'-diyl)diphenol 
• 880644-75-7 8,8'-bis(p-anisyl-p-phenyl)-3,3'-biisoquinoline 
• 880644-67-7 8,8'-bis(4-methoxyphenyl)-3,3'-biisoquinoline 
• 880644-74-6 8-(p-anisyl-p-phenyl)isoquinolin-3-yl trifluoromethanesulfonate 
• 880644-72-4 8-(p-anisyl-p-phenyl)isoquinolin-3-yl benzoate 
• 880644-66-6 8-(p-anisyl)isoquinolin-3-yl trifluoromethanesulfonate 
• 880644-73-5 8-(p-anisyl-p-phenyl)isoquinolin-3-ol 
• 880644-70-2 8-bromo-isoquinoline-3-benzoyl ester 

Relevant articles and documents

BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation: (I).

A new family of biisoquinoline chelates

Four 8,8′-diaryl-substituted 3,3′-biisoquinoline ligands have been synthesized and characterized. The key feature of this new family of chelates is their endotopic but sterically non-hindering nature. All four ligands were made from a common 8-bromoisoquinolin-3-ol precursor; between three and twelve synthetic steps were necessary to obtain the products. The reported synthetic procedures allow for gram-scale production of these biisoquinolines. Wiley-VCH Verlag GmbH & Co. KGaA, 2007.